RARE – Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.RARE
$36.52Name : Ultragenyx Pharmaceutical Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,452,673,792.00
EPSttm : -5.83
Ultragenyx Pharmaceutical Inc.
$36.52
1.62%$0.6Float Short %
6.88
Margin Of Safety %
Put/Call OI Ratio
0.55
EPS Next Q Diff
0.26
EPS Last/This Y
0.97
EPS This/Next Y
1.76
Price
36.53
Target Price
87.47
Analyst Recom
1.21
Performance Q
-6.09
Relative Volume
2.62
Beta
0.26
Ticker: RARE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | RARE | 36.14 | 0.55 | 0.06 | 34735 |
| 2025-06-03 | RARE | 36.24 | 0.53 | 0.50 | 35621 |
| 2025-06-04 | RARE | 36.62 | 0.53 | 0.58 | 36064 |
| 2025-06-05 | RARE | 36.93 | 0.52 | 17.92 | 36738 |
| 2025-06-06 | RARE | 37.17 | 0.52 | 1.95 | 36866 |
| 2025-06-09 | RARE | 37.04 | 0.52 | 0.03 | 37381 |
| 2025-06-10 | RARE | 37.67 | 0.51 | 3.54 | 37951 |
| 2025-06-11 | RARE | 37.35 | 0.51 | 1.04 | 37889 |
| 2025-06-12 | RARE | 39.31 | 0.59 | 1.28 | 42404 |
| 2025-06-13 | RARE | 37.49 | 0.61 | 0.02 | 44314 |
| 2025-06-16 | RARE | 37.11 | 0.64 | 3.38 | 43338 |
| 2025-06-17 | RARE | 36.66 | 0.64 | 0.02 | 43482 |
| 2025-06-18 | RARE | 37.35 | 0.55 | 0.28 | 48305 |
| 2025-06-20 | RARE | 37.14 | 0.49 | 1.23 | 59615 |
| 2025-06-23 | RARE | 36.82 | 0.51 | 1.07 | 57236 |
| 2025-06-24 | RARE | 37.32 | 0.51 | 2.99 | 57295 |
| 2025-06-25 | RARE | 37.41 | 0.53 | 1.35 | 57711 |
| 2025-06-26 | RARE | 37.12 | 0.54 | 12.47 | 59458 |
| 2025-06-27 | RARE | 36.51 | 0.55 | 0.57 | 59831 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | RARE | 36.17 | 12.7 | - | -5.32 |
| 2025-06-03 | RARE | 36.40 | 12.7 | - | -5.32 |
| 2025-06-04 | RARE | 36.60 | 12.7 | - | -5.32 |
| 2025-06-05 | RARE | 36.91 | 12.7 | - | -5.32 |
| 2025-06-06 | RARE | 37.19 | 12.7 | - | -5.32 |
| 2025-06-09 | RARE | 37.04 | 12.7 | - | -5.32 |
| 2025-06-10 | RARE | 37.51 | 12.7 | - | -5.32 |
| 2025-06-11 | RARE | 37.52 | 12.7 | - | -5.32 |
| 2025-06-12 | RARE | 39.29 | 12.7 | - | -5.32 |
| 2025-06-13 | RARE | 37.51 | 12.7 | - | -5.32 |
| 2025-06-16 | RARE | 37.10 | 12.7 | - | -5.32 |
| 2025-06-17 | RARE | 36.66 | 12.7 | - | -5.32 |
| 2025-06-18 | RARE | 37.35 | 12.7 | - | -5.32 |
| 2025-06-20 | RARE | 37.14 | 12.7 | - | -5.32 |
| 2025-06-23 | RARE | 36.83 | 12.7 | - | -5.32 |
| 2025-06-24 | RARE | 37.15 | 12.7 | - | -5.32 |
| 2025-06-25 | RARE | 37.38 | 12.7 | - | -5.32 |
| 2025-06-26 | RARE | 37.15 | 12.7 | - | -5.32 |
| 2025-06-27 | RARE | 36.53 | 12.7 | - | -5.32 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | RARE | -2.87 | 2.52 | 6.67 |
| 2025-06-03 | RARE | -2.87 | 2.52 | 6.67 |
| 2025-06-04 | RARE | -2.87 | 2.52 | 6.67 |
| 2025-06-05 | RARE | -2.87 | 2.52 | 6.67 |
| 2025-06-06 | RARE | -2.87 | 2.52 | 6.67 |
| 2025-06-09 | RARE | -2.87 | 2.53 | 6.67 |
| 2025-06-10 | RARE | -2.87 | 2.53 | 6.67 |
| 2025-06-11 | RARE | -2.87 | 2.53 | 6.28 |
| 2025-06-12 | RARE | -2.74 | 2.53 | 6.28 |
| 2025-06-13 | RARE | -2.74 | 2.53 | 6.28 |
| 2025-06-16 | RARE | -2.74 | 2.85 | 6.28 |
| 2025-06-17 | RARE | -2.74 | 2.85 | 6.28 |
| 2025-06-18 | RARE | -2.74 | 2.85 | 6.28 |
| 2025-06-20 | RARE | -2.74 | 2.85 | 6.28 |
| 2025-06-23 | RARE | -2.78 | 2.57 | 6.28 |
| 2025-06-24 | RARE | -2.78 | 2.57 | 6.28 |
| 2025-06-25 | RARE | -2.78 | 2.57 | 6.28 |
| 2025-06-26 | RARE | -2.78 | 2.57 | 6.88 |
| 2025-06-27 | RARE | -2.78 | 2.57 | 6.88 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.57
Avg. EPS Est. Current Quarter
-1.33
Avg. EPS Est. Next Quarter
-1.31
Insider Transactions
-2.78
Institutional Transactions
2.57
Beta
0.26
Average Sales Estimate Current Quarter
161
Average Sales Estimate Next Quarter
164
Fair Value
Quality Score
39
Growth Score
54
Sentiment Score
7
Actual DrawDown %
79.7
Max Drawdown 5-Year %
-82.5
Target Price
87.47
P/E
Forward P/E
PEG
P/S
5.85
P/B
23.73
P/Free Cash Flow
EPS
-5.88
Average EPS Est. Cur. Y
-5.32
EPS Next Y. (Est.)
-3.56
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-93.04
Relative Volume
2.62
Return on Equity vs Sector %
-404.9
Return on Equity vs Industry %
-387
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Ultragenyx Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1294
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading